What Are Danaher Investors Betting On?

For questions about this article or underlying research, email help@trefis.com.

Danaher (DHR) stock trades at 34.2 times its earnings over the last twelve months. This multiple uses adjusted earnings: normalized profit with stock-based pay added back after tax. That represents a steep price for a single year of profit. The forecasts below count profit on management’s adjusted basis, which differs from this measure, so much of any gap between the multiples is a difference in measure rather than expected growth. So what do buyers paying that price expect Danaher to earn in fiscal 2026 and fiscal 2027?

Danaher Investors Expect Profit To Grow Faster Than Sales

The consensus forecast has Danaher’s profit rising 9.1% in fiscal 2027. That is a little faster than sales, which the forecast puts up 7.6% from fiscal 2026. Based on this outlook, Danaher’s $160 billion market value at the November 2 close is 26.4 times its fiscal 2026 profit. Under the forecast for fiscal 2027, the same price represents 24.2 times profit.

The forecast puts Danaher’s net margin at 23.2% in fiscal 2026 and 23.5% in fiscal 2027, meaning most of the profit growth expected in fiscal 2027 comes from sales. Both margins are higher than the 14.7% Danaher reported for fiscal 2025. Because the forecast counts adjusted profit and the 14.7% is reported profit, the two are not directly comparable.

Is Danaher Growing As Fast As Investors Expect?

Partly. Danaher’s sales grew 3.7% from a year earlier in fiscal Q1 2026, 5.5% in fiscal Q2 2026, and growth reached 8.3% in fiscal Q3 2026. The core business did not produce all of the third quarter’s growth. On its October 21 call, management put core revenue growth at 3%, noting it was held back by lower respiratory sales.

Over the twelve months to September 2026, Danaher’s sales grew 5.5%, meaning the business has not yet grown as fast as the forecast expects for fiscal 2027. Fiscal 2026 profit looks largely settled. Management raised its fiscal 2026 guide for adjusted earnings per share to $8.57-$8.62, and the $8.59 forecast sits inside that range.

Where Could Danaher Investors Be Wrong?

The forecast is most likely to fall short on fiscal 2027 sales. For 2027, management called 4%-5% core revenue growth excluding respiratory revenue the right starting point. That figure represents its own measure rather than total sales. Management also plans for respiratory sales of $1.5 billion in 2027. Because this matches 2026 levels, those sales add no growth. To meet the forecast, the remaining sales growth would have to come from faster expansion than management expects, from deals like the StatLab acquisition by Danaher’s Leica Biosystems in early fiscal Q4 2026, or from items outside management’s core measure. If none of these factors closes that difference, the fiscal 2027 sales forecast would come down, taking the profit forecast with it.

Respiratory sales can also move the forecast either way. Management planned for a middle-of-the-road flu season and said flu seasons vary from year to year. As a result, a mild season could pull fiscal 2027 sales below the plan, and a heavy one could lift them above it.

If Danaher delivers the forecast, the price on fiscal 2027 profit provides a fair picture of what you pay today. If fiscal 2027 sales fall short, the stock is priced for profit Danaher may not deliver, making it a riskier bet. Management’s fiscal 2027 outlook for core revenue growth, expected with Danaher’s fourth-quarter report in January 2027, is the number to watch.

Sitting On A Big Gain In Danaher?

After a run like this, the hard questions are personal: hold, trim or sell, and the tax on each. Our partner advisory firm offers a free strategy review of ways to keep part of the upside, protect the rest and spread the tax over years.

Request A Free Strategy Review

Spot an error or want more like this? Tell us in 10 seconds.